Medical isotope developer IsoRay Medical has entered into an exclusive distribution agreement with Aurora BioScience to handle its complete product line in Australia and New Zealand.
IsoRay called Aurora BioScience the ideal choice to support its products, which leverage the structure of the cesium-131 isotope to attack prostate cancer, as well as other cancers including brain, head and neck, lung, and gynecologic. The company believes that global recognition of the power of cesium-131 through published studies is leading to increased attention for its products.
IsoRay said it continues to invest in R&D focusing on the efficacy of cesium-131 for cancers throughout the body, and it expects to see a direct financial impact due to its growing array of nonprostate-cancer treatments.
